Key Details
Price
$234.28Annual Revenue
$1.83 BAnnual EPS
-$3.52Annual ROE
199.53%Beta
0.52Events Calendar
Next earnings date:
Feb 14, 2025Recent quarterly earnings:
Oct 31, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
This is a comparison of how Alnylam Pharmaceuticals (ALNY) and argenx SE (ARGX) have done in relation to their industry up to this point in the year.
Alnylam (ALNY) has received a Zacks Rank #2 (Buy) upgrade, indicating increased confidence in the company's potential earnings. This could lead to a rise in the stock price soon.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a top company in RNAi therapeutics, has announced that its management will give a company overview at the Piper Sandler 36th Annual Healthcare Conference on Thursday, December 5, 2024, at 11:00 am ET, held at the Lotte New York Palace Hotel in New York City. You can listen to a live audio webcast of the presentation on the Investors section of the company's website at www.alnylam.com/events, and a replay will also be accessible.
ALNY has announced that it has submitted a supplemental New Drug Application (sNDA) in the United States. This application aims to expand the use of Amvuttra for treating ATTR amyloidosis that affects the heart.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a top company in RNAi therapeutics, has shared new findings from its Phase 1 study of nucresiran (previously known as ALN-TTRsc04), which is being developed to treat transthyretin (ATTR) amyloidosis. The results were presented during an oral session at the American Heart Association Scientific Sessions 2024 in Chicago. These findings showed that a single dose of the treatment had significant effects.
The transcript of Alnylam Pharmaceuticals, Inc. (ALNY) earnings call for the third quarter of 2024 is available.
Alnylam Pharmaceuticals is a top company in RNAi therapies, having several FDA-approved treatments and a strong lineup aimed at rare and serious diseases. The company has great potential for growth, especially with Amvuttra for ATTR-CM, which may generate significant revenue in an expanding market. Furthermore, vutrisiran for ATTR-CM could take a large portion of an estimated $11.2 billion market.
Is Alnylam Pharmaceuticals (ALNY) a strong choice for momentum investors? Let's explore this question.
This is a comparison of how Alnylam Pharmaceuticals (ALNY) and ANI Pharmaceuticals (ANIP) have done in relation to their industry this year.
Alnylam's sales of Amvuttra and Givlaari are helping to increase their revenue. Their partnerships with RHHBY, NVS, and REGN are also moving forward successfully.
FAQ
- What is the primary business of Alnylam Pharmaceuticals?
- What is the ticker symbol for Alnylam Pharmaceuticals?
- Does Alnylam Pharmaceuticals pay dividends?
- What sector is Alnylam Pharmaceuticals in?
- What industry is Alnylam Pharmaceuticals in?
- What country is Alnylam Pharmaceuticals based in?
- When did Alnylam Pharmaceuticals go public?
- Is Alnylam Pharmaceuticals in the S&P 500?
- Is Alnylam Pharmaceuticals in the NASDAQ 100?
- Is Alnylam Pharmaceuticals in the Dow Jones?
- When was Alnylam Pharmaceuticals's last earnings report?
- When does Alnylam Pharmaceuticals report earnings?
- Should I buy Alnylam Pharmaceuticals stock now?